+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07788196

Comparing Anti-HER2 Therapy Plus Chemotherapy Versus Chemotherapy Alone as Post-Surgery Treatment for Stage IB-II HER-2 Positive Gastric Cancer

Led by Xijing Hospital · Updated on 2026-08-26

120

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multicenter randomized controlled trial involving 120 patients with HER-2-positive gastric cancer at stages IB to II following surgery. The study aims to compare the effectiveness of combining anti-HER2 therapy with chemotherapy versus chemotherapy alone as adjuvant treatment after tumor resection. This Phase 2 trial is led by Xijing Hospital and involves 11 medical centers working together in China. Participants are randomly assigned to one of two groups. The control group receives chemotherapy appropriate to their cancer stage stage IB patients take oral tegafur twice daily for 14 days in six 21-day cycles, while stage II patients receive either the SOX or XELOX chemotherapy regimens, both including intravenous oxaliplatin on Day 1 plus oral drugs for 14 days per cycle, over six cycles. The experimental group receives the same chemotherapy regimens plus intravenous trastuzumab, starting with a loading dose followed by maintenance doses, administered concurrently with chemotherapy during six 21-day cycles. During the study, participants will be monitored for disease-free survival over five years after randomization, which is the primary outcome. Overall survival will also be tracked for up to five years. Assessments include safety and organ function evaluations before and during treatment. Participants will be involved in regular visits aligned with their chemotherapy cycles and followed long-term to measure treatment outcomes and monitor health status throughout the study duration.

CONDITIONS

Brief Title

A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.

Research Team

Y

Yongzhan Nie

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here